期刊
MELANOMA RESEARCH
卷 31, 期 4, 页码 402-404出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CMR.0000000000000757
关键词
B-raf (BRAF); dabrafenib; hypersensitivity reaction
Type I hypersensitivity reactions to dabrafenib are rare but can occur in patients with BRAF-mutated melanoma. In this case, a desensitization protocol with encorafenib was successful in allowing the patient to continue treatment, suggesting it as a potential option for patients with limited therapeutic alternatives.
Type I hypersensitivity reactions (HSR) to dabrafenib are rare but have been previously described. We present a case where a 72-year-old woman with recurrent, metastatic BRAF-mutated melanoma developed a type I HSR to dabrafenib. We, therefore, developed a desensitization protocol with encorafenib, a similar class agent, to allow the patient to continue with treatment. Patients with a history of HSR to dabrafenib may be considered for encorafenib desensitization when other therapeutic options are limited.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据